Published on 02/12/2025

Qualification of Contract Labs for E&L: What to Audit

Extractables and leachables (E&L) studies are crucial components in ensuring the safety and efficacy of pharmaceutical products, particularly in the context of packaging systems and container closure integrity. This comprehensive guide aims to provide pharmaceutical professionals with a structured approach to the qualification of contract analytical laboratories involved in E&L assessments. This article will define the scope of E&L studies, highlight audit checklists, and summarize best practices to comply with regulatory requirements from authorities such as the US FDA, EMA, and MHRA.

Understanding Extractables and Leachables (E&L)

The terms extractables and leachables refer to the chemical substances that can migrate from packaging materials into pharmaceutical products. Extractables are substances that can be extracted from the material under conditions of intense testing, while leachables are the compounds that migrate under normal storage conditions. E&L assessments are vital in evaluating the potential risks these substances pose to drug products.

The significance of E&L studies is underscored by guidelines such as the FDA’s guidance and EU GMP Annex 1. These documents emphasize the importance of a thorough risk assessment, which includes determining analytical evaluation threshold (AET) and dose-based threshold (DBT) evaluations. An effective E&L risk assessment process should engage stakeholders from Quality Assurance (QA), Quality Control (QC), and Regulatory Affairs (RA) teams to ensure compliance.

Initial Audit Preparations

Before conducting an audit of contract laboratories, it is essential to establish the scope and objectives of the audit. Determine the specific E&L testing methodologies relevant to your pharmaceutical products, which may include testing for various compound classes such as plasticizers, antioxidants, and other polymer additives.

Follow these preparatory steps:

• Define the Scope: Identify which E&L studies (e.g., extractables, leachables, studies on single-use systems) require laboratory qualification.
• Gather Previous Audit Reports: Review past audit reports of the laboratories, if available, to identify strengths and weaknesses.
• Review Regulatory Guidelines: Ensure familiarity with applicable regulatory guidelines pertaining to E&L evaluations, such as the USP standards for container closure integrity (CCI).
• Assemble an Audit Team: Involve cross-functional team members who possess expertise in regulatory affairs, quality assurance, and analytical chemistry.

Conducting the Audit

Audits of contract laboratories should be systematic and comprehensive. Focus on critical areas related to E&L assessments and laboratory operations. Utilize a structured audit checklist to ensure no crucial aspect is overlooked. Here are key components to evaluate during the audit:

1. Laboratory Compliance

Assess whether the laboratory is compliant with GLP (Good Laboratory Practice) and cGMP (current Good Manufacturing Practice) standards. Verify that the laboratory holds appropriate licenses and certifications.

2. Technical Capabilities

Evaluate the laboratory’s technical capabilities and testing methodologies for E&L studies. This includes checking the sensitivity and specificity of analytical techniques employed, such as chromatography and mass spectrometry.

3. Equipment Qualification

Review documentation related to equipment qualification, including installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ). Ensure that instruments used for E&L testing are regularly calibrated and maintained.

4. Method Validation

Examine the protocols for method validation to confirm that analytical methods in use are robust and reproducible. It is vital to verify that methods adhere to both FDA and EMA regulatory requirements.

5. Data Integrity

Data integrity is paramount in ensuring accurate E&L assessments. Confirm that the laboratory implements strict practices to maintain data integrity, including audit trails, access controls, and established electronic health record systems.

6. Personnel Training and Competency

Assess the training programs for laboratory personnel to ensure that they are adequately trained in E&L testing techniques and understand regulatory requirements.

Post-Audit Actions and Decision Making

Once the audit is complete, the next steps involve analyzing the findings and determining the overall qualifications of the contract laboratory based on the audit results.

1. Analyze Audit Results

Summarize the findings from the audit, paying attention to both strengths and areas of improvement. Evaluate whether the laboratory is capable of meeting the requirements for E&L testing under current regulations.

2. Follow-Up Actions

Work with the laboratory to address identified deficiencies. The contract lab should provide a corrective action plan detailing how they will rectify any issues raised during the audit.

3. Document Everything

It is critical to maintain thorough documentation throughout the audit process. Detailed records will serve as valuable references, which are particularly important during future regulatory inspections or audits.

Establishing Ongoing Audit Practices

To ensure continuous compliance and quality assurance regarding E&L studies, implement a program of periodic audits of contract laboratories. This ongoing evaluation process should include regular reassessments based on previous findings and updates to regulatory guidelines.

Here are some best practices for implementing an effective audit program:

• Create a Schedule: Establish a regular audit schedule that aligns with manufacturing and testing cycles.
• Incorporate Unannounced Audits: Conduct unannounced audits periodically to verify continuous compliance.
• Engage in Continuous Improvement: Foster a culture of continuous improvement by sharing findings with the laboratory and discussing areas for future enhancement.

Understanding Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

The determination of AET and DBT is a pivotal aspect of E&L risk assessments. AET is the minimum amount of an extractable or leachable that could potentially elicit an adverse effect, while DBT refers to the exposure limit based on the specific dosage of the drug product. Understanding these thresholds is fundamental to evaluating safety and regulatory compliance.

Follow these steps to establish AET and DBT:

• Identify Relevant Toxicological Data: Gather toxicological information applicable to potential leachables identified in E&L studies.
• Apply AET Calculation Methods: Apply the most current methodologies to calculate the AET, considering factors such as route of exposure and patient population.
• Evaluate Dose-Based Threshold: Conduct a dose-based assessment to align with industry practices and standards, which might include references from established guidelines such as those provided by the Probiotic Quality Research Initiative (PQRI).

Container Closure Integrity (CCI) in E&L Assessments

Container closure integrity is essential for protecting drug products from contamination and maintaining their stability. The integrity of the container impacts the potential for leachables and must be evaluated thoroughly during E&L studies.

To assess CCI effectively:

• Select Appropriate Testing Methods: Choose suitable methods for CCI testing, such as vacuum decay and dye ingress methodologies.
• Set Acceptance Criteria: Establish scientifically justified acceptance criteria consistent with regulatory standards (e.g. USP).
• Document Test Conditions: Provide comprehensive documentation of test conditions, including the environment and equipment used.

Implementation of Single-Use Systems Validation

With the increasing reliance on single-use systems in pharmaceutical manufacturing, it is critical to integrate single-use systems validation into the E&L framework. Proper validation ensures that leachables from these systems do not compromise product safety.

The following points should be addressed in single-use systems validation:

• Compatibility Assessments: Investigate the compatibility of materials used in single-use systems with the intended pharmaceutical products.
• Conduct E&L Studies: Include dedicated E&L studies for single-use systems to quantify any potential leachables that may migrate into drug products.
• Evaluate End-of-Life Parameters: Assess how the integrity of single-use systems is maintained during product storage and administration.

Conclusion and Best Practices for E&L Studies

Qualifying contract labs for extractables and leachables studies is an essential strategy to ensure robust compliance with FDA, EMA, and other regulatory standards. A structured approach to audits, ongoing evaluations, and thorough documentation are imperative to support quality assurance and regulatory compliance.

By adhering to the outlined steps and best practices in this guide regarding E&L studies, pharmaceutical professionals can enhance their proficiency in managing E&L risks while ensuring the safety and quality of drug products.

Staying informed about evolving guidance from regulatory agencies such as the FDA and EMA, as well as complying with industry best practices, is vital for optimal outcomes in E&L assessments.